ClinicalTrials.gg
Not yet recruitingNCT06924723Updated Apr 11, 2025

Effect of Standardized Lacrimal Sac Massage Compared With Probing for Congenital Lacrimal Duct Obstruction

An interventional study of tear duct probing and Lacrimal sac massage in Nasolacrimal Duct Obstruction, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Not yet recruiting. Open to participants aged 3 Months to 1 Year. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
3 Months to 1 Year
Sex
All
01

Study summary

Congenital nasolacrimal duct obstruction (CNLDO) is a common ophthalmic condition in children, presenting with tearing and pus overflow, with a prevalence of 5%-20% within 1 year of age. Although most cases resolve spontaneously within 1 year of age, some children require treatment. Lacrimal sac massage is a non-invasive, easy and cost-effective conservative treatment that helps to unblock the obstruction by increasing the pressure in the tear duct. Studies have shown that massage has a 93% cure rate in children under 8 months of age. In contrast, tear duct probing is effective but invasive and risky. In recent years, with the development of minimally invasive techniques, lacrimal sac massage has received renewed attention, and studies have shown its efficacy to be comparable to probing. However, there are problems of non-standardized massage timing and techniques in clinical practice, which affects the therapeutic efficacy. This study aims to assess whether the efficacy of standardized dacryocystic massage is not inferior to that of dacryocystorhinostomy through a randomized controlled trial, providing a reference for the treatment of CNLDO.

02

Conditions studied

  • Nasolacrimal Duct Obstruction
03

In context

Lacrimal Duct Obstruction

41 studies on the registry are indexed under Lacrimal Duct Obstruction; 8 are open to participants now.

This study's planned enrollment of 160 is above the median of 75 across 30 interventional studies indexed under Lacrimal Duct Obstruction.

Browse Lacrimal Duct Obstruction studies →

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 164 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age from 3 months to 1 year;
  2. Presence of at least one symptom of CNLDO (tear spillage, mucous discharge) in one or both eyes;
  3. No surgical treatment for NLD (probing, balloon dilation, tube placement, DCR, etc.);
  4. Can cooperate with the examination and subsequent follow-up;
  5. Guardians agreed to be enrolled in the study and signed an form.

Exclusion criteria

Exclusion Criteria:

  1. Combination of presenting infections of the conjunctiva and cornea;
  2. Combination of other serious ocular surface and intraocular disorders that may affect the therapeutic effect;
  3. Congenital malformation syndromes, developmental delays, facial anomalies, facial deformities; history of surgery or injury to the lacrimal duct, history of punctal occlusion, history of lacrimal fistula, history of congenital bulging of the lacrimal sac, history of acute dacryocystitis, history of severe blepharitis, and perinatal abnormalities such as preterm labor, low birth weight, and so on;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    control subjects

    Procedure: tear duct probing

  • Experimental
    experimental group

    Procedure: Lacrimal sac massage

Interventions

  • Proceduretear duct probing

    In-office tear duct exploratory surgery was performed on the study participants, and the children were closely monitored for healing after the procedure. The children were closely monitored for healing afterward, and the patients were also examined at 1 week, 1 month, and 2 months after the start of treatment.

  • ProcedureLacrimal sac massage

    At the time of the visit, the patient's parents (one of them) were given Standardized tear duct massage (Crigler massage)Teaching and hands-on practice were performed, with the researcher confirming the standardization of movements.Subsequent massages were performed by the family member who received the training, and the child's family swiped the card to access the program.completed by the family member of the child, who scanned the code to enter the small program punch card group, according to the standardized process of massage (the frequency of massage was not less than 3 times/day, each time no less than 4 eight beats)And complete the punch card on time (each punch card interval should be greater than 2 hours).(each clock interval should be more than 2 hours).

06

What researchers measure

Primary outcomes

  1. Treatment success of congenital tear duct obstruction at 3 months of treatment

    Cure rate of congenital lacrimal obstruction at 3 months of treatment: patients with symptoms of lacrimal obstruction (tearing, pus overflow) disappeared are considered cured; lacrimal irrigation patency rate at 3 months of treatment (all lacrimal irrigation fluid goes into the throat, and no reflux is considered to be patency)

    Time frame: At 3 months of starting treatment

Secondary outcomes

  1. Lacrimal flushing patency at 3 months after the start of treatment

    Whether the tear duct flushing is smooth

    Time frame: at 3 months after the start of treatment

  2. Incidence of complications during treatment

    Counting adverse events over the course of 3 months of treatment

    Time frame: at 3 months after the start of treatment

  3. Recurrence of symptoms within 1 month of cure

    Observe whether the patient has recurrence of tearing and pus overflow symptoms within 1 month after cure

    Time frame: 1 month after cure

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06924723
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
May 1, 2025 (estimated)
Primary completion
Oct 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Apr 11, 2025

Study contacts

Xuanwei Liang
Contact
liangxuanwei@163.com
+8613694220662

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion